Table 3.
Monoclonal antibody therapies against SARS-CoV-2 infection tested in NHP models.
| mAb | Description | Animal Model Used in Preclinical Studies | Antiviral and Clinical Effects | Toxicity Data | Clinical Studies | Reference |
|---|---|---|---|---|---|---|
| REGN- COV2 | Cocktail of two potent neutralizing antibodies (REGN10987+ REGN10933) targeting non-overlapping epitopes on the SARS-CoV-2 spike protein |
RhM | Prophylactic administration led to strongly reduced viral load. | N/A | NCT04425629 | [66] |
| LY-CoV555 | Cocktail of two human IgG1 mAbs targeting different epitopes on the SARS-CoV-2 spike protein | RhM | Prophylactic administration led to lower viral loads and reduced viral shedding. | N/A | NCT04411628 NCT04427501 NCT04497987 NCT04501978 | [68] |
| MW05/LALA | SARS-CoV-2 Spike glycoprotein RBD-targeting mAb | RhM | Potent therapeutic and prophylactic effect on SARS-CoV-2 infection and clinical disease. | None | N/A | [74] |
| COVA1-18 | SARS-CoV-2 Spike glycoprotein RBD-targeting mAb | CyM, hACE2 mice, Syrian hamster | PreP in CyM led to strong protection, prophylactic administration led to potent reduction of viral load in the lungs. | N/A | None | [73] |
N/A: not available; RhM: Rhesus Macaque; CyM: Cynomolgus Macaques.